Sage Therapeutics, Inc. (SAGE): Price and Financial Metrics

Sage Therapeutics, Inc. (SAGE): $18.74

0.30 (-1.58%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add SAGE to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#161 of 365

in industry

SAGE Price/Volume Stats

Current price $18.74 52-week high $59.99
Prev. close $19.04 52-week low $16.51
Day low $18.51 Volume 1,004,600
Day high $19.34 Avg. volume 963,598
50-day MA $22.73 Dividend yield N/A
200-day MA $25.77 Market Cap 1.13B

SAGE Stock Price Chart Interactive Chart >

SAGE POWR Grades

  • SAGE scores best on the Growth dimension, with a Growth rank ahead of 52.18% of US stocks.
  • The strongest trend for SAGE is in Growth, which has been heading up over the past 26 weeks.
  • SAGE's current lowest rank is in the Sentiment metric (where it is better than 3.59% of US stocks).

SAGE Stock Summary

  • For SAGE, its debt to operating expenses ratio is greater than that reported by just 4.84% of US equities we're observing.
  • With a price/sales ratio of 114.5, SAGE THERAPEUTICS INC has a higher such ratio than 97.88% of stocks in our set.
  • With a year-over-year growth in debt of -49.39%, SAGE THERAPEUTICS INC's debt growth rate surpasses merely 5.14% of about US stocks.
  • Stocks that are quantitatively similar to SAGE, based on their financial statements, market capitalization, and price volatility, are LUMO, TDUP, QSI, PALI, and RYTM.
  • SAGE's SEC filings can be seen here. And to visit SAGE THERAPEUTICS INC's official web site, go to www.sagerx.com.

SAGE Valuation Summary

  • In comparison to the median Healthcare stock, SAGE's EV/EBIT ratio is 112.33% lower, now standing at -1.8.
  • SAGE's price/earnings ratio has moved up 29.1 over the prior 115 months.

Below are key valuation metrics over time for SAGE.

Stock Date P/S P/B P/E EV/EBIT
SAGE 2023-12-29 114.5 1.6 -2 -1.8
SAGE 2023-12-28 116.6 1.6 -2 -1.8
SAGE 2023-12-27 117.6 1.6 -2 -1.8
SAGE 2023-12-26 117.1 1.6 -2 -1.8
SAGE 2023-12-22 115.5 1.6 -2 -1.8
SAGE 2023-12-21 113.4 1.6 -2 -1.7

SAGE Growth Metrics

    The 3 year revenue growth rate now stands at -93.05%.
  • Its year over year net income to common stockholders growth rate is now at -176%.
  • The 5 year cash and equivalents growth rate now stands at 38.2%.
SAGE's revenue has moved down $1,003,000 over the prior 34 months.

The table below shows SAGE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 7.686 -460.036 -532.784
2022-09-30 6.464 -430.605 -510.35
2022-06-30 6.165 -380.566 -503.198
2022-03-31 6.307 -376.896 -484.183
2021-12-31 6.308 -378.182 -457.892
2021-09-30 1,113.852 730.29 641.715

SAGE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SAGE has a Quality Grade of C, ranking ahead of 62.22% of graded US stocks.
  • SAGE's asset turnover comes in at 0.544 -- ranking 73rd of 681 Pharmaceutical Products stocks.
  • VTGN, SVRA, and SESN are the stocks whose asset turnover ratios are most correlated with SAGE.

The table below shows SAGE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.544 0.999 0.571
2021-06-30 0.637 0.999 0.746
2021-03-31 0.767 0.999 0.960
2020-12-31 0.954 0.999 1.092
2020-09-30 0.008 0.907 -0.813
2020-06-30 0.009 0.929 -0.814

SAGE Price Target

For more insight on analysts targets of SAGE, see our SAGE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $85.11 Average Broker Recommendation 1.66 (Moderate Buy)

Sage Therapeutics, Inc. (SAGE) Company Bio


Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS, disorders. The company was founded in 2010 and is based in Cambridge, Massachusetts.


SAGE Latest News Stream


Event/Time News Detail
Loading, please wait...

SAGE Latest Social Stream


Loading social stream, please wait...

View Full SAGE Social Stream

Latest SAGE News From Around the Web

Below are the latest news stories about SAGE THERAPEUTICS INC that investors may wish to consider to help them evaluate SAGE as an investment opportunity.

11 Most Promising Psychedelic Stocks According to Hedge Funds

In this piece, we will take a look at the 11 most promising psychedelic stocks according to hedge funds. If you want to skip our overview of the psychedelic industry and the latest news, then you can take a look at the 5 Most Promising Psychedelic Stocks. The ability to use chemicals to alter one’s […]

Yahoo | December 20, 2023

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD Patient support program, ZURZUVAE For You, and financial assistance available to eligible women with PPD prescribed ZURZUVAE Patients will receive prescriptions directly at home via specialty pharmacy distribution model CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therap

Yahoo | December 14, 2023

Why Is Sage Therapeutics, Inc. (SAGE) Up 12.7% Since Last Earnings Report?

Sage Therapeutics, Inc. (SAGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 7, 2023

Strong week for Sage Therapeutics (NASDAQ:SAGE) shareholders doesn't alleviate pain of five-year loss

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...

Yahoo | December 2, 2023

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2023 Earnings Call Transcript

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good morning. Welcome to Sage Therapeutics’ Third Quarter 2023 Conference Call. [Operator Instructions]. This call is being webcast live on the Investors and Media section of Sages’ website at sagerx.com. This call is the property of Sage Therapeutics and recording, reproduction or […]

Yahoo | November 13, 2023

Read More 'SAGE' Stories Here

SAGE Price Returns

1-mo -17.48%
3-mo -13.52%
6-mo -8.94%
1-year -57.16%
3-year -73.83%
5-year -88.22%
YTD -13.52%
2023 -43.18%
2022 -10.34%
2021 -50.83%
2020 19.84%
2019 -24.64%

Continue Researching SAGE

Here are a few links from around the web to help you further your research on Sage Therapeutics Inc's stock as an investment opportunity:

Sage Therapeutics Inc (SAGE) Stock Price | Nasdaq
Sage Therapeutics Inc (SAGE) Stock Quote, History and News - Yahoo Finance
Sage Therapeutics Inc (SAGE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!